On October 28, 2025, Akebia Therapeutics announced that it will not proceed with the VALOR clinical trial for vadadustat due to lack of alignment with the FDA, impacting its plans for treating anemia in non-dialysis patients with CKD. This event is considered significant and negatively perceived by investors as it halts potential market opportunities for the drug.